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Supplementary clinical data, treatment results and additional 
immunohistochemistry data of FL3B cases.  
 
Supplementary data of FL3B cases 
 106 
The patients included in this study are all adults and were diagnosed as 
FL3B at time of the obtained biopsy. Patients were classified using clinical data 
and treatment data for both primary and secondary FL3B. The clinical data from 
28 patients with the primary and secundary diagnosis FL3B are summarised in 
Table A1. From 2 patients was no clinical data available and in 2 cases it concerns 
a sequential biopsy.  
 
The treatment data includes details of treatment in 18 patients with the  
primary diagnosis FL3B (Table A2a). Ten patients were diagnosed with NHL and 
treated before the biopsy was obtained on which the diagnosis FL3B was based 
and of which the cytogenetic results were obtained (Table A2b).  
 
In addition, we investigated our panel of 30 cases with special emphasis on 
BCL6, CD10 and MUM1/IRF4 expression and the 3 different subgroups with  
I: a 3q27 abberation and no t(14;18), II: a subgroup with none of these abberations 














Table A1: Clinical Data.from 28 patients with the diagnosis FL3B. 
  N=28 % 
Age Median: 57.6  
 Range: 29-85  
Sex Male: 17 61% 
 Female: 11 39% 
B-symptoms Yes: 4 13% 
Clinical stage I-IA: 5 18% 
 II: 8 28% 
 III-IV: 15 54% 
WHO performance score 1-2: 7 25% 
 3-4: 0 0% 
BM involvement Yes: 7 25% 
E-localisation 1 Yes: 9 32% 
Bulky mass 2 Yes: 7 25% 
LDH >> 3 Yes: 10 36% 
IP-index 0-1: 16 57% 
 2-3: 12 43% 
 4-5: 0 0% 
Survival 
First diagnosis -








 other than BM 
2 > 10 cm 
3 normal = < 400 
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Table A2a: Cytogenetic grouping and treatment results of 18 patients with the primary diagnosis FL3B. 
Subgroup Case primary diagnosis Primary therapy Response No of relapses Subtype OS 
Ia 2 FL3B 6xCHOP + XRT PR ?  ? GC ?? 
I 25 FL3B 12xCHOP-like CR 1  DOC GC 14 months 
I 29 FL3B XRT 3500Gy CR 0  A GC? > 4.5 years 
II 9 FL3B Excision lymphnode CR 1  A (NED) GC > 3years 
II 12 Rec.na 
prim.FL3B 
6xCHOP, 5xCEP CR 2  A (NED) GC > 9 years 
II 8 FL3B 6xCHOP CR 0  A (NED) ABC > 9 years 
II 15 FL3B 4xCHOP PD 1  DOD ABC 1.5 years 
II 16 FL3B 1xCHOP,4xCOP,1xCHOP, 1xCHOP PR 1  AWD GC > 8 years 
II 18 FL3B 7xCHOP,1xmini-BEAM PD 0  DOD GC 7 months 
II 19 FL3B 4xCHOP,1xDHAP,1xmini-BEAM NR/PD 0  DOD GC 9 months 
II 32 FL3B XRT 40Gy (2 months) CR 0  A (NED) ?? > 4 years 
III 10 FL3B 5xCP PR 1  DOC GC 2 years 
III 11 FL3B 3xCHOP,1xXRT 30Gy CR 0  A (NED) GC > 7 years 
III 13 FL3B 6xCHOP CR 3  A (NED) GC > 6 years 
III 20 FL3B 8xCHOP CR 0  A (NED) GC > 7 years 
III 21 FL3B 6xCHOP/MTX,after 17 months x8 CR 3  DOD ?? 4.5 years 
III 26 FL3B 12xVACOP-B ,XRT2500Gy,+other PR/CR 1  DOD GC 4 years 
III 27 FL3B 12xVACOP-B + XRT250Gy CR 0  A (NED) GC > 8 years 
I: t(14;18) negative and 3q27 positive, II: t(14;18) and 3q27 negative, III: t(14;18) positive and 3q27 negative, a : incomplete data; A: Alive, D: Dead, AWD: alive with disease, DOD: 
dead of disease, DOC: dead of other cause, NED: no evidence of disease. GC: Germinal Center like lymphoma, ABC: Activated B-Cell lymphoma, CR: complete response, PR: partial 
response, PD: partial disease, NR: no response, OS: overall survival 
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Table A2b: Cytogenetic grouping of 10 patients with an antecedent NHL diagnosis, treatment results and time to diagnosis 
FL3B. 







relapses Subtype OS 
10; 
6;5;2 




years I 17 FL1,2 MVPP,chl.amb,CHOP,DHAP,XRT CR/PR 
17 
months  
    





I 6 FL3B? Leukeran/plasmapheresis PR 4 years 3xCHOP PR 2  DOD ABC 
5 
years 
I 30 FL1,2 Prednisolone (10wks) PR 5 years No therapy CR 1  A (NED) GC 
> 14 
years 
II 1 IBL./DLBCL 7xCHOP CR 10 












III 7 FL1,2 8x fludarabine PR 20 
















years III 28 FL1,2 
 
CR 17 years 
     




I: t(14;18) negative and 3q27 positive, II: t(14;18) and 3q27 negative, III: t(14;18) positive and 3q27 negative 
A: Alive, D: Dead, AWD: alive with disease, DOD: dead of disease, DOC: dead of other cause, NED: no evidence of disease. 
GC: Germinal Center like B-cell lymphoma, ABC: Activated B-Cell lymphoma, CR: complete response, PR: partial response, PD: partial disease, NR: no response, OS: overall survival
Supplementary data of FL3B cases 
110 








subtype Primary diagnosis  
 I:  3q27 break  
no t(14;18) 
        
2 + + - GC FL3B 
6 + - + ABC FL3B ->FL3B? 
17 + - - GC FL1,2 ->FL3B 
22** + ND ND     FL3B  
25 +/- + - GC FL3B 
29 + - - ? GC? FL3B 
30 + - - CG FL1,2 ->FL3B 
4 + - + ABC DLBCL ->FL3B 
         
 II:  no 3q27 
break  
no t(14;18) 
        
1 + - + ABC IBL ->FL3B 
5 + - + ABC DLBCL ->FL3B 
8 + - + ABC FL3B 
15** + - + ABC FL3B 
16 + - - GC FL3B 
18 + + - GC FL3B 
19 + + -  GC FL3B 
24 ++ -  - ? GC? no data  
32 + -     FL3B  
9 + - - GC FL3B 
12 + + + GC FL3B 
         
 III:  t(14;18)  
 no 3q27 break 
       
7 + ND ND   FL1,2 FL3B 
10 +  + - GC FL3B 
11 +  - ND GC FL3B 
13 +  + - GC FL3B 
14 +  + - GC FL1,2 FL3B 
20 +  - - GC FL3B 
21 ND ND ND   FL3B 
26 ND  + ND GC FL3B 
27 ND  + - GC FL3B 
28 ND  - -   FL1,2 FL3B 
31 +  + ND GC FL1,2 FL3B 
 
GC: Germinal Center like B-cell lymphoma, ABC: Activated B-Cell lymphoma 
ND: not done, ^ 3q27 pos. with Southern Blot hybridization; ** cases with a sequential biopsy. 
